3-Dehydromitragynine: Metabolism, Toxicology & Evidence Gaps

What is 3-dehydromitragynine?

3-Dehydromitragynine, abbreviated 3DM in the 2021 primary study, is an oxidative metabolite of mitragynine. It deserves a separate toxicology discussion: it is not another name for 7-hydroxymitragynine or mitragynine pseudoindoxyl, and their opioid findings cannot be substituted for its findings. Metabolism study

Safety boundary: This review provides no consumer dose, synthesis instructions, or recommendation to use an isolated metabolite. An uncertain exposure pathway does not establish safety. See the site's medical disclaimer.

Human evidence

The cited studies do not establish a controlled human exposure-response relationship for isolated 3DM. They also do not establish that this metabolite explains a particular human kratom poisoning or death. That distinction matters when a laboratory finding is used to answer a question about a person: detecting a hazard in an experimental model and attributing a clinical event require different evidence.

This review makes no claim that 3DM is a useful treatment. Evidence about mitragynine, botanical kratom, or concentrated 7-OH is not a clinical trial of 3DM, even when those substances are chemically connected.

Preclinical evidence

The 2021 study detected 3DM after mitragynine administration in mouse plasma and brain and reported lethality after direct experimental administration in multiple mouse strains. The authors explicitly noted uncertainty about exposure and half-life after direct administration. These results warrant investigation without supporting a human dose conversion. Primary study

The route, species, experimental exposure, and measured endpoint must stay attached to this finding. Direct administration of a laboratory compound is not equivalent to the amount formed after human consumption of a botanical product. Neither a reassuring nor an alarming clinical incidence estimate can be calculated from these experiments alone.

Pharmacology and receptors

3DM did not show antinociception in the mouse experiments. Toxicity persisted in mu-opioid-receptor knockout mice and with delta/kappa receptor antagonists, supporting an opioid-receptor-independent toxicity hypothesis in those models. This does not identify the responsible human toxicological target. Receptor experiments

A lack of demonstrated analgesic activity should not be interpreted as a lack of biological activity. Conversely, belonging to the mitragynine chemical family does not justify labeling every member a clinically active opioid.

Metabolism and pharmacokinetics

Laboratory work identified a non-CYP formation pathway from mitragynine. A 2026 analytical study also described 3-dehydromitragynine formation from 7-OH under simulated gastric conditions. Simulated digestion is not evidence of the amount formed in a living person, its absorption, or its contribution to poisoning. 2021 metabolism · 2026 stability analysis

Human clearance, tissue concentrations, accumulation, and the influence of product composition remain unresolved in the evidence reviewed here. A clinical interpretation needs validated sampling that can distinguish metabolites formed in the body from changes during sample handling.

Safety

The direct mouse toxicity signal is the principal compound-specific concern. It does not provide a safe exposure threshold for humans. A retail product label also cannot establish how much of this metabolite a person will form. The FDA's broader kratom warnings provide product-level context, rather than proof that 3DM caused those reported harms. FDA

Dependence and withdrawal

Compound-specific human dependence and withdrawal evidence is not established by these studies. Kratom or 7-OH withdrawal reports cannot be relabeled as 3DM withdrawal. The absence of those data leaves this question unanswered; it does not support calling 3DM non-addictive.

Interactions

No clinical interaction study of isolated 3DM was identified among the primary sources reviewed. The non-CYP formation finding does not demonstrate that enzyme inhibitors will prevent toxicity, or that a medication combination is safe. There is no evidence basis here for a protective combination or a self-treatment strategy.

Regulatory status — September 30, 2026

This review does not establish a jurisdiction-wide legal status for isolated 3DM. Do not infer its status from a related compound's scheduling or from online availability. FDA's kratom page addresses botanical products and health risks; it is not a compound-specific legal clearance for this metabolite. FDA

Evidence gaps

Priorities are validated human metabolite detection, exposure measurements, identification of toxicological targets, independent replication, and clinical attribution. Until then, the defensible answer is a preclinical toxicity signal with unresolved human relevance, rather than an established explanation of kratom mortality.

Related compounds

• Mitragynine: parent alkaloid and the human-evidence anchor.
• 7-Hydroxymitragynine: a distinct opioid-active metabolite.
• Mitragynine pseudoindoxyl: rearranged derivative with separate withdrawal and regulatory evidence.
• Speciociliatine, speciogynine, and mitraciliatine: separate kratom alkaloids, not synonyms for 3DM.

The substance-use evidence hub connects the broader safety and dependence literature. Primary references and identifiers are listed below.